{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075680","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.090240+00:00","generated_at":"2026-05-17T16:23:19.500065+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Carisma stockholders approve reverse stock split at ratio of 1:10 to 1:50","bullets":["Stockholders adopted reverse split amendment; board has sole discretion to set exact ratio (1:10 to 1:50) and timing.","Vote results: 21,783,014 for, 3,352,989 against, 92,853 abstain.","Adjournment proposal also approved but was not needed due to quorum and sufficient votes for the reverse split.","No further stockholder approval is required for implementation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075680","json":"https://secwatch.observer/filing/0001104659-25-075680.json","markdown":"https://secwatch.observer/filing/0001104659-25-075680.md","text":"https://secwatch.observer/filing/0001104659-25-075680.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925075680/0001104659-25-075680-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925075680/tm2522922d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:23:19.500065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}